Misplaced Pages

Temoporfin

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by BogBot (talk | contribs) at 00:58, 3 September 2011 (populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 00:58, 3 September 2011 by BogBot (talk | contribs) (populated new fields in {{drugbox}} and reordered per bot approval. Report errors and suggestions to User_talk:BogBot)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound
Temoporfin
Clinical data
AHFS/Drugs.comInternational Drug Names
License data
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
IUPAC name
  • 3,3',3'',3'''-(2,3-dihydroporphyrin-5,10,15,20-tetrayl)tetraphenol
CAS Number
PubChem CID
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.152.970 Edit this at Wikidata
Chemical and physical data
FormulaC44H32N4O4
Molar mass680.74 g/mol g·mol
3D model (JSmol)
SMILES
  • C1CC2=NC1=C(C3=CC=C(N3)C(=C4C=CC(=N4)C(=C5C=CC(=C2C6=CC(=CC=C6)O)N5)C7=
  (verify)

Temoporfin (INN) is a photosensitizer (based on porphyrin) used in photodynamic therapy for the treatment of squamous cell carcinoma of the head and neck . It is marketed in the European Union under the brand name Foscan. The US FDA deemed Foscan non-approvable in 2000. The EU approved its use in June 2001.

Good results were obtained in 21 of 35 patients treated in Germany.

It is photoactivated at 652 nm i.e. by red light.

Patients can remain photosensitive for several weeks after treatment.

Further reading

References

  1. Lorenz KJ, Maier H (2008). "". HNO (in German). 56 (4): 402–9. doi:10.1007/s00106-007-1573-1. PMID 17516041. {{cite journal}}: Unknown parameter |month= ignored (help)
  2. ^ O'Connor, Aisling E, Gallagher, William M, Byrne, Annette T (2009). "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy. Photochemistry and Photobiology, Sep/Oct 2009". Photochemistry and Photobiology.{{cite news}}: CS1 maint: multiple names: authors list (link)
  3. http://www.highbeam.com/doc/1P2-18794532.html Foscan approval saves Scotia's skin.
  4. http://www.springerlink.com/content/g74w224824v8l013/
  5. "Porphyrin and Nonporphyrin Photosensitizers in Oncology: Preclinical and Clinical Advances in Photodynamic Therapy". Photochemistry and Photobiology. 2009.
Intracellular chemotherapeutic agents / antineoplastic agents (L01)
SPs/MIs
(M phase)
Block microtubule assembly
Block microtubule disassembly
DNA replication
inhibitor
DNA precursors/
antimetabolites
(S phase)
Folic acid
Purine
Pyrimidine
Deoxyribonucleotide
Topoisomerase inhibitors
(S phase)
I
II
II+Intercalation
Crosslinking of DNA
(CCNS)
Alkylating
Platinum-based
Nonclassical
Intercalation
Photosensitizers/PDT
Other
Enzyme inhibitors
Receptor antagonists
Other/ungrouped


Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Misplaced Pages by expanding it.

Categories: